Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | IKBKB | O14920 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929057 | 0.94 | IKBKB (0.45) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1928481 | 0.84 | CHEK1 (0.51) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1926507 | 0.83 | CHEK1 (0.53) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1928723 | 0.81 | JAK2 (0.46) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1926589 | 0.81 | CHEK1 (0.54) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1929091 | 0.79 | IKBKB (0.44) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1927898 | 0.75 | MCHR1 (0.41) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1928545 | 0.75 | TBK1 (0.43) | JAK2IKBKBMEN1KMT2AJAK3 | |
| SCHEMBL1987192 | 0.71 | CHEK1 (0.42) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL1929724 | 0.68 | IKBKB (0.55) | JAK2IKBKBMEN1EIF2AK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | claimed |
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | JAK2 166/4885IKBKB 3173/4885MEN1 1642/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | JAK2 422/4885IKBKB 2989/4885MEN1 1990/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | JAK2 166/4885IKBKB 3173/4885MEN1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.